瘤内 T 细胞受体重组可预测胰腺导管腺癌患者的总生存率

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-03-15 DOI:10.1080/2162402x.2024.2320411

Vikram S. Pothuri, Graham D. Hogg, Leah Conant, Nicholas Borcherding, C. Alston James, Jacqueline Mudd, Greg Williams, Yongwoo David Seo, William G. Hawkins, Venu G. Pillarisetty, David G. DeNardo, Ryan C. Fields

引用次数: 0

摘要

胰腺导管腺癌（PDAC）是一种致命的恶性肿瘤，对免疫检查点抑制剂疗法难治。然而，瘤内T细胞浸润与总体病情改善相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is refractory to immune checkpoint inhibitor therapy. However, intratumoral T-cell infiltration correlates with improved overall ...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.